

TARO PHARMACEUTICALS INC.

BALANCE SHEETS

	March 31, 2024 (Unaudited) USD Dollars	March 31, 2023 (Unaudited) USD Dollars
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 318,784,382	\$ 116,608,187
Short-term bank deposits	31,447,079	64,500,000
Marketable securities	390,428,886	502,862,139
Trade accounts receivable	30,463,622	27,124,034
Other receivables and prepaid expenses:		
Prepaid expenses	2,062,306	2,731,111
Deferred income taxes	-	-
Government authorities	601,864	5,208,198
Advances to suppliers	241,865	5,366,036
Derivative instruments	-	-
Intercompany balances and Loan	340,940,534	344,491,028
Other	9,572,192	8,183,594
TOTAL Other receivables and prepaid expenses	<u>353,418,761</u>	<u>365,979,966</u>
Inventories	<u>76,527,903</u>	<u>84,762,552</u>
TOTAL CURRENT ASSETS	1,201,070,635	1,161,836,878
LONG-TERM RECEIVABLES AND OTHER ASSETS	376,359,212	335,222,210
FIXED ASSETS:		
Cost	166,335,719	127,812,792
Less - accumulated depreciation	<u>(79,819,462)</u>	<u>(71,055,919)</u>
	86,516,257	56,756,874
GOODWILL	276,147	276,147
INTANGIBLE ASSETS AND DEFERRED COSTS, NET	58,367,192	68,108,506
INVESTMENT IN ASSOCIATED COMPANIES	372,600,002	372,600,002
INVESTMENT IN PARTNERSHIPS	3,500,000	2,000,000
DEFERRED INCOME TAXES	2,516,918	16,844,499
TOTAL ASSETS	<u>\$ 2,101,206,362</u>	<u>\$ 2,013,645,115</u>

TARO PHARMACEUTICALS INC.

BALANCE SHEETS

	March 31, 2024 (Unaudited) USD Dollars	March 31, 2023 (Unaudited) USD Dollars
LIABILITIES AND SHAREHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Accounts payable:		
Trade payables	\$ 19,648,503	\$ 34,835,563
Other current liabilities:		
Returns reserve	7,694,673	8,186,473
Due to customers	-	-
Intercompany balances	42,974	5,196,275
Employees and payroll accruals	5,756,520	4,250,073
Deferred revenue	236,624	236,624
Medicaid and indirect rebates	6,403,136	6,054,342
Accrued income taxes	1,665,574	-
Legal and audit fees	-	-
Accrued expenses	17,275,214	15,459,510
Interest payable	-	-
Derivative instruments	-	-
Deferred taxes	-	-
Other	293,874	286,859
TOTAL Other current liabilities	39,368,588	39,670,155
TOTAL CURRENT LIABILITIES	59,017,091	74,505,719
LONG-TERM LIABILITIES:		
Deferred income taxes	-	-
Other long-term liabilities	1,876,930	10,873,924
	1,876,930	10,873,924
SHAREHOLDERS' EQUITY	2,040,312,341	1,928,265,472
	\$ 2,101,206,362	\$ 2,013,645,115

Date of approval of the
financial statements

Thurga S. Mayuran
Senior Director, Finance

STATEMENTS OF INCOME

	For the year Ended March 31, 2024 (Unaudited) USD Dollars	For the year Ended March 31, 2023 (Unaudited) USD Dollars	For the year Ended March 31, 2022 (Unaudited) USD Dollars
Sales	\$ 312,859,580	\$ 271,761,033	\$ 288,772,111
Cost of sales	<u>184,560,395</u>	<u>176,877,851</u>	<u>169,630,345</u>
Gross profit	128,299,185	94,883,181	119,141,765
Research and development	27,948,387	18,802,130	19,598,992
Selling and marketing expenses	17,999,356	11,613,777	10,750,192
General and administrative expenses	<u>8,392,108</u>	<u>8,726,055</u>	<u>8,100,916</u>
Operating income	73,959,333	55,741,220	80,691,666
Settlements and Loss Contingencies	-	-	18,623,673
Financing income (expenses), net	55,650,532	20,343,481	9,327,570
Other income (expense)	<u>1,259,040</u>	<u>(1,810)</u>	<u>60,911</u>
Income before taxes on income	130,868,905	76,082,891	71,456,473
Taxes on income	<u>23,823,131</u>	<u>8,990,394</u>	<u>12,994,735</u>
Net income for the period before subsidiaries and dividend	107,045,773	67,092,498	58,461,738
Dividend income, net	-	-	-
Subsidiaries	<u>-</u>	<u>-</u>	<u>-</u>
Net income for the period	<u>\$ 107,045,773</u>	<u>\$ 67,092,498</u>	<u>\$ 58,461,738</u>

TARO PHARMACEUTICALS INC.

Changes in Shareholders' Equity

USD Dollars

Unaudited

	Number of Shares (Unaudited)	Share Capital (Unaudited)	Additional Paid-in Capital (Unaudited)	Accumulated Other Comprehensive Income (Loss) (Unaudited)	Foreign Currency Translation Adj (Unaudited)	Retained Earnings (Unaudited)	Total Taro Shareholders' Equity (Unaudited)	Noncontrolling Interest (Unaudited)	Total Shareholders' Equity (Unaudited)
Balance at March 31, 2021 (USD)	12	372,607,244	263,098	4,468,094	(156,753,284)	1,595,947,180	1,816,532,332	-	1,816,532,332
Comprehensive income, net of tax	-	-	-	(13,855,093)	-	-	(13,855,093)	-	(13,855,093)
Net income	-	-	-	-	-	58,461,738	58,461,738.00	-	58,461,738
Balance at March 31, 2022 (USD)	12	372,607,244	263,098	(9,386,999)	(156,753,284)	1,654,408,918	1,861,138,977	-	1,861,138,977
Comprehensive income, net of tax	-	-	-	33,997	-	-	33,997	-	33,997
Net income	-	-	-	-	-	67,092,498	67,092,498.00	-	67,092,498
Balance at March 31, 2023 (USD)	12	372,607,244	263,098	(9,353,002)	(156,753,284)	1,721,501,416	1,928,265,472	-	1,928,265,472
Comprehensive income, net of tax	-	-	-	5,001,095	-	-	5,001,095	-	5,001,095
Net income (loss)	-	-	-	-	-	107,045,773	107,045,773	-	107,045,773
Balance at March 31, 2024 (USD)	12	372,607,244	263,098	(4,351,906)	(156,753,284)	1,828,547,189	2,040,312,341	-	2,040,312,341